ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results. Management will also provide a brief update on the business.


To access the live call by phone, dial (877) 621-5803; the conference ID is 5444669. The call may also be accessed through the Investors and Media section of the Company’s website, Following the call, a replay will be available at the same location.


ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at

INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney O'Konek 781-895-0600


FTI Consulting Robert Stanislaro 212-850-5657

Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ImmunoGen Charts.
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ImmunoGen Charts.